



The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.

Notice of extraordinary general meeting in Cyxone AB

The shareholders of Cyxone AB, Reg. No. 559020-5471 (“**Cyxone**”), are hereby invited to an extraordinary general meeting on Friday 27 October at 13.00 CEST, at the company’s office, Hyllie Stationstorg 31 in Malmö, Sweden.

Right to participate

Shareholders wishing to attend the extraordinary general meeting must:

- be registered in the company’s share register kept by Euroclear Sweden AB as of Thursday 19 October 2023, and
- have notified their participation no later than Monday 23 October 2023, by mail to Cyxone AB, Hyllie Boulevard 34, SE-215 32 Malmö, Sweden or by e-mail to admin@cyxone.com. The notification should specify the shareholder’s complete name, personal identity number or company registration number, the number of shares held by the shareholder, address, telephone number during work hours and, when applicable, information on the number of advisors (two at the most).

Trustee-registered shares

Shareholders whose shares are trustee-registered in the name of a bank or other trustee must, to be able to exercise their voting rights at the meeting by advance voting, request the trustee to register their shares in their own name with Euroclear Sweden AB (so called “voting rights registration”). Such voting rights registration must be implemented by the trustee no later than as of Monday 23 October 2023. Accordingly, shareholders must well in advance before this date notify their trustee of their request of such voting rights registration.

Proxy

In case the shareholder should be represented by a proxy, the proxy must bring a written power of attorney, which is dated and duly signed by the shareholder, to the meeting. The validity term of the power of attorney may not be more than one year, unless a longer validity term is specifically stated in the power of attorney (however at the longest five years). If the power of attorney is issued by a legal entity, the representing proxy must also present a valid registration certificate or equivalent document for the legal entity. In order to facilitate the entrance at the meeting, a copy of the power of attorney and other authorization documents should preferably be attached to the shareholder's notification to participate in the meeting. Proxy forms are available on the company’s website (www.cyxone.com) and are sent by post to shareholders who contact the company and provide their address.

Proposed agenda

1. Opening of the meeting.
2. Election of Chairman of the meeting.

Press release

Cyxone AB (publ)
559020-5471
25 September 2023



3. Preparation and approval of the register of voters.
4. Approval of agenda.
5. Election of two persons to confirm the minutes.
6. Determination as to whether the meeting has been duly convened.
7. Resolution to decrease the share capital for allocation to unrestricted equity.
8. Resolution on amendment of the Articles of Association.
9. Resolution on approval of the board of directors' resolution on rights issue of shares.
10. Resolution on authorization for the board of directors to resolve on new issues of shares.
11. Closing of the meeting.

Proposed resolutions

Item 2: Election of Chairman of the meeting

The board of directors proposes that lawyer Ola Grahn is elected as Chairman of the meeting.

Item 7: Resolution to decrease the share capital for allocation to unrestricted equity

The board of directors proposes that the extraordinary general meeting shall resolve on a share capital decrease of SEK 3,491,999.378868 for allocation to unrestricted equity and without withdrawal of shares. The reason for the board of directors' proposal on the share capital decrease is to improve the relation between the share capital and unrestricted equity.

As a statement under Chapter 20, Section 13 of the Swedish Companies Act (*Sw. aktiebolagslagen* (2005:551)) the board of directors states the following. The resolution on share capital decrease in accordance with the proposal in this item can be implemented without an authorization from the Swedish Companies Registration Office (*Sw. Bolagsverket*) or the general court, since the company will at the same time carry out a rights issue of shares, which results in that neither the company's restricted equity nor share capital together will decrease. The board of directors' resolution of a rights issue of shares, subject to the approval of the extraordinary general meeting, is set out in item 9 on the agenda to the meeting.

The effect of the board of directors' proposal for a resolution on share capital decrease in accordance with this item is that the share capital and restricted equity will decrease by SEK 3,491,999.378868 to SEK 3,937,789.120, whereby at the same time the share's quota value decreases from SEK 0.075 to SEK 0.04. The effect upon full subscription of the rights issue is that the share capital and restricted equity thereafter will increase by SEK 8,531,876.08 (based on the new quota value) to SEK 12,469,665.20. If the rights issue is only subscribed for at the guaranteed level (approximately 55 per cent), the share capital and restricted equity will increase by SEK 4,692,531.84 to SEK 8,630,320.96.

The resolution to decrease the share capital presupposes and is conditional upon the general meeting resolving to amend the Articles of Association and approve the rights issue in accordance with the board of director's proposal to the extraordinary general meeting.

Press release

Cyxone AB (publ)
559020-5471
25 September 2023



The company's CEO shall be authorized to make such minor formal adjustments of the resolution as might be necessary in connection with registration with the Swedish Companies Registration Office (*Sw. Bolagsverket*).

Item 8: Resolution on amendment of the Articles of Association

The board of directors proposes that the extraordinary general meeting resolves to amend the company's Articles of Association in accordance with the following:

§ 4 Share capital*Current wording*

The share capital of the company shall be no less than SEK 3,773,583 and no more than SEK 15,094,332.

Proposed wording

The share capital of the company shall be no less than SEK 8,200,000 and no more than SEK 32,800,000.

§ 5 Number of shares*Current wording*

The number of shares shall not be less than 50,000,000 and shall not exceed 200,000,000.

Proposed wording

The number of shares shall not be less than 205,000,000 and shall not exceed 820,000,000.

The resolution to amend the Articles of Association presupposes is and conditional upon the general meeting resolving to decrease the share capital and approve the rights issue in accordance with the board of director's proposal to the extraordinary general meeting.

The company's CEO shall be authorized to make such minor formal adjustments of the resolution as might be necessary in connection with registration with the Swedish Companies Registration Office (*Sw. Bolagsverket*).

Item 9: Resolution on approval of the board of directors' resolution on rights issue of shares

The board of directors proposes that the extraordinary general meeting resolves to approve the board of directors' resolution of 25 September 2023 to increase the company's share capital with at the highest SEK 8,531,876.08 (based on the quota value of the share after the reduction of the share capital as proposed in item 7 of the agenda of the general meeting) through the issue of at the highest 213,296,902 shares and on the following terms and conditions:

1. SEK 0.17 shall be paid for each new share, whereby the amount that exceeds the share's quota value shall be allocated to the free share premium reserve.
2. Subscription of shares shall be made by exercise of subscription rights. The right to receive subscription rights for subscription of new shares with preferential rights shall vest in those who, on the record date, are registered as shareholders and thereby are allotted subscription rights in relation to their shareholding as of the record date.
3. The record date for right to participate in the rights issue shall be on 3 November 2023.

Press release

Cyxone AB (publ)
559020-5471
25 September 2023



4. Each existing share entitles to 1 subscription right and 6 subscription rights entitle to subscription of 13 new shares.
5. If not all shares are subscribed for by exercise of subscription rights, allotment of the remaining shares shall be made within the highest amount of the issue:
 - (i) firstly, to those who have subscribed for shares by exercise of subscription rights (regardless of whether they were shareholders on the record date or not) and who have applied for subscription of shares without exercise of subscription rights and if allotment to these cannot be made in full, allotment shall be made pro rata in relation to the number of subscription rights that each and every one of those, who have applied for subscription of shares without exercise of subscription rights, have exercised for sub-scription of shares;
 - (ii) secondly, to those who have applied for subscription of shares without exercise of subscription rights and if allotment to these cannot be made in full, allotment shall be made pro rata in relation to the number of shares the subscriber in total has applied for subscription of shares; and
 - (iii) thirdly, to those who have provided guarantee commitments with regard to subscription of shares, in proportion to such guarantee commitments.

To the extent that allotment in any section above cannot be done pro rata, allotment shall be determined by drawing of lots.

6. Subscription of shares by exercise of subscription rights shall be made through cash payment during the time period from and including 7 November 2023 to and including 21 November 2023. Subscription of shares without exercise of subscription rights shall be made on a special application form during the same time period. Payment for shares subscribed for without exercise of subscription rights is to be made no later than the third banking day after notification of allotment has been sent to the subscriber by a promissory note. The board of directors shall have the right to prolong the time period for subscription and payment.
7. The new shares convey right to dividends as from the first record date for dividends occurring after the issue resolution.
8. The company's CEO shall be authorized to make such minor formal adjustments of the resolution as might be necessary in connection with registration with the Swedish Companies Registration Office or Euroclear Sweden AB.
9. The resolution on the rights issue presupposes and is conditional upon the general meeting resolving on a decrease of the share capital and on an amendment of the Articles of Association in accordance with the board of director's proposal to the general meeting.

Item 10: Resolution on authorization for the board of directors to resolve on new issues of shares

In order to enable new issues of shares as guarantee compensation to those that have entered into guarantee undertakings in order to secure the rights issue of shares to be approved under item 9 on the agenda of the extraordinary general meeting (the "**Guarantors**"), the board of

Press release

Cyxone AB (publ)
559020-5471
25 September 2023



directors proposes that the extraordinary general meeting resolves to authorize the board of directors, up until the next annual general meeting, at one or several occasions, with deviation from the shareholders' preferential rights, and with or without provisions regarding set-off or other provisions, to resolve on new issues of shares to the Guarantors. Upon exercise of the authorization, the subscription price shall correspond to the subscription price in the rights issue. The purpose of the authorization and reason for the deviation from the shareholders' preferential rights is to be able to carry out new issues of shares as guarantee compensation to the Guarantors. The number of ordinary shares that may be issued through the authorization shall not exceed the total number of ordinary shares that corresponds to the agreed guarantee compensation that the company shall pay to the Guarantors. Other terms and conditions of the issue shall be determined by the board of directors.

The resolution to authorize the board of directors to resolve on new issues of ordinary shares presupposes is and conditional upon the general meeting resolving to approve the rights issue in accordance with the board of director's proposal to the extraordinary general meeting.

The company's CEO shall be authorized to make such minor formal adjustments of the resolution as might be necessary in connection with registration with the Swedish Companies Registration Office (Sw. Bolagsverket).

Particular majority requirements

For valid resolutions on the proposals pursuant to items 7, 8 and 10 the proposals have to be supported by shareholders representing at least two-thirds of the votes cast as well as of all shares represented at the meeting.

Shareholder's right to information

Shareholders who are present at the meeting have the right to request information regarding circumstances that may affect the assessment of an item of the agenda pursuant to chapter 7, section 32, paragraph 1 of the Swedish Companies Act (2005:551).

Meeting documents and other information

The complete proposals for the resolutions and ancillary documents pursuant to the Swedish Companies Act will be available at the company's office, at Hyllie Stationstorg 31, 215 32 Malmö, Sweden and at the company's website (www.cyxone.com) as from no later than two weeks prior to the meeting, and will also be sent to shareholders who request it and provide their address. The share register of the meeting will also be available at the company's office.

Number of shares and votes

The total number of shares and votes in the company amounts to 98,444,728. The company does not hold any own shares.

Processing of personal data

For information on how your personal data is processed, see <https://www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf>.

Press release
Cyxone AB (publ)
559020-5471
25 September 2023



Malmö in September 2023
Cyxone AB (publ)
The Board of Directors

Contact

Carl-Magnus Högerkorp, CEO
Tel: +46 (0)70 781 88 12
Email: carl.hogerkorp@cyxone.com

The information was submitted for publication, through the agency of the contact person set out above on 25 September 2023.

About Cyxone

Cyxone AB (publ) (Nasdaq First North Growth Market: CYXO) develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis. Rabeximod is a Phase 2 candidate drug being evaluated for the management of rheumatoid arthritis. T20K is a Phase 1 candidate drug for treatment of multiple sclerosis. Certified Adviser is FNCA Sweden AB. For more information, please visit www.cyxone.com